We scan new podcasts and send you the top 5 insights daily.
Historically, neuroscience has suffered high clinical failure rates due to heterogeneous patient groups, complex pathologies, and subjective, squishy endpoints. Adopting oncology's playbook of validating objective biomarkers and stratifying patient sub-populations before clinical entry allows drug developers to de-risk trials and verify target engagement early.
Instead of a traditional biomarker-first approach, Alto took a drug already approved in Europe (agomelatine) and used machine learning on patient EEG data to discover a novel biomarker that predicts who responds best. This "reverse-engineering" approach de-risks development by finding a precise population for a proven drug.
Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.
In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.
An analysis of over 17,000 oncology drug development trajectories revealed that trials incorporating biomarkers had almost twice the overall success probability (10%) compared to those without (5%). This success boost is most significant in early-phase (Phase 1 and 2) trials.
The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.
To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.
The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.
Pharma's renewed interest in neuroscience is not for early-stage discovery. They are underwriting late-stage, de-risked assets with human proof-of-concept, understood mechanisms, and biomarker data. This strategy allows them to buy optionality on validated programs while avoiding the high cost of early failures.
Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.
Unlike big pharma, capital-constrained biotechs can't afford long, expensive trials. MindImmune’s CEO advocates for designing clever Phase 1b studies that use biomarker endpoints to get an early efficacy signal in months, not years, thereby de-risking the program for investors much faster.